NCT04556838: A trial that was reported late by VivaVision Biotech, Inc
This trial has reported, although it was 35 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04556838 |
|---|---|
| Title | A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 Compared to Vehicle in Subjects With Dry Eye Disease |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 3, 2020 |
| Completion date | Dec. 1, 2021 |
| Required reporting date | Dec. 1, 2022, midnight |
| Actual reporting date | Jan. 5, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 35 |